Visual outcome following chemotherapy for progressive optic pathway gliomas

Pediatric Blood and Cancer

Volumn 57, Issue 3, 2011, Pages 481-485

  Shofty, Ben ^a,b   Ben Sira, Liat ^a,b   Freedman, Sigal ^a   Yalon, Michal ^c   Dvir, Rina ^a,b   Weintraub, Michael ^d   Toledano, Hagit ^a   Constantini, Shlomi ^a,b   Kesler, Anat ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Chemotherapy; Glioma; OPG; Optic pathway; Visual outcome

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; ERLOTINIB; ETOPOSIDE; IRINOTECAN; RAPAMYCIN; TEMOZOLOMIDE; VINBLASTINE; VINCRISTINE;

ALLERGY; ARTICLE; BLINDNESS; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FOLLOW UP; GLIOMA; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NEUROOPHTHALMOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC PATHWAY GLIOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; TREATMENT FAILURE; TUMOR GROWTH; TUMOR REGRESSION; VISION; VISUAL ACUITY; VISUAL DEPRIVATION; VISUAL SYSTEM;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; OPTIC NERVE GLIOMA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINCRISTINE; VISION, OCULAR; VISUAL ACUITY;

EID: 79960153889     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22967     Document Type: Article

References (29)

1. Shamji MF, Benoit BG. Syndromic and sporadic pediatric optic pathway gliomas: Review of clinical and histopathological differences and treatment implications. Neurosurg Focus 2007; 23: E3.
2. Dutton JJ. Gliomas of the anterior visual pathway. Surv Ophthalmol 1994; 38: 427-452.
3. Listernick R, Ferner RE, Liu GT, et al. Optic pathway gliomas in neurofibromatosis-1: Controversies and recommendations. Ann Neurol 2007; 61: 189-198.
4. Packer RJ. Chemotherapy: Low-grade gliomas of the hypothalamus and thalamus. Pediatr Neurosurg 2000; 32: 259-263.
5. Sharif S, Ferner R, Birch JM, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: Substantial risks after radiotherapy. J Clin Oncol 2006; 24: 2570-2575.
6. Guillamo JS, Creange A, Kalifa C, et al. Prognostic factors of cns tumours in neurofibromatosis 1 (nf1): A retrospective study of 104 patients. Brain 2003; 126: 152-160.
7. Binning MJ, Liu JK, Kestle JR, et al. Optic pathway gliomas: A review. Neurosurg Focus 2007; 23: E2.
8. Leonard JR, Perry A, Rubin JB, et al. The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1. Neurology 2006; 67: 1509-1512.
9. Pepin SM, Lessell S. Anterior visual pathway gliomas: The last 30 years. Semin Ophthalmol 2006; 21: 117-124.
10. Reddy AT, Packer RJ. Chemotherapy for low-grade gliomas. Childs Nerv Syst 1999; 15: 506-513.
11. Packer RJ, Lange B, Ater J, et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 1993; 11: 850-856.
12. Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997; 86: 747-754.
13. Lancaster DL, Hoddes JA, Michalski A. Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas. J Neurooncol 2003; 63: 289-294.
14. Prados MD, Edwards MS, Rabbitt J, et al. Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol 1997; 32: 235-241.
15. Lafay-Cousin L, Holm S, Qaddoumi I, et al. Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer 2005; 103: 2636-2642.
16. Tosoni A, Franceschi E, Ermani M, et al. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol 2008; 89: 179-185.
17. Gururangan S, Fisher MJ, Allen JC, et al. Temozolomide in children with progressive low-grade glioma. Neuro Oncol 2007; 9: 161-168.
18. Sawamura Y, Kamoshima Y, Kato T, et al. Chemotherapy with cisplatin and vincristine for optic pathway/hypothalamic astrocytoma in young children. Jpn J Clin Oncol 2009; 39: 277-283.
19. Packer R, Yalon M, Rood B, et al. Phase I/II study of tarceva/rapamycin for recurrent pediatric low-grade gliomas (lgg). Neuro Oncol 2010; 12: ii20.
20. Parsa CF, Hoyt CS, Lesser RL, et al. Spontaneous regression of optic gliomas: Thirteen cases documented by serial neuroimaging. Arch Ophthalmol 2001; 119: 516-529.
21. Rozen WM, Joseph S, Lo PA. Spontaneous regression of low-grade gliomas in pediatric patients without neurofibromatosis. Pediatr Neurosurg 2008; 44: 324-328.
22. Campagna M, Opocher E, Viscardi E, et al. Optic pathway glioma: Long-term visual outcome in children without neurofibromatosis type-1. Pediatr Blood Cancer 2010; 55: 1083-1088.
23. Moreno L, Bautista F, Ashley S, et al. Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence. Eur J Cancer 2010; 46: 2253-2259.
24. Dalla Via P, Opocher E, Pinello ML, et al. Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program. Neuro Oncol 2007; 9: 430-437.
25. Nicolin G, Parkin P, Mabbott D, et al. Natural history and outcome of optic pathway gliomas in children. Pediatr Blood Cancer 2009; 53: 1231-1237.
26. Margalit N, Kesler A, Ezer H, et al. Tuberculum and diaphragma sella meningioma-surgical technique and visual outcome in a series of 20 cases operated over a 2.5-year period. Acta Neurochir (Wien) 2007; 149: 1199-1204, discussion 1204.
27. Dodge HW, Jr., Love JG, Craig WM, et al. Gliomas of the optic nerves. AMA Arch Neurol Psychiatry 1958; 79: 607-621.
28. Taylor T, Jaspan T, Milano G, et al. Radiological classification of optic pathway gliomas: Experience of a modified functional classification system. Br J Radiol 2008; 81: 761-766.
29. Fisher MJ, Balcer L, Gutmann DH, et al. Neurofibromatosis type i associated optic glioma visual outcomes following chemotherapy: An international multi-center retrospective analysis. Neuro Oncol 2010; 12: ii19-ii20.